As for BRAF mutations (the most frequent is BRAFV600E corresponding to almost 95%), they are considered an unfavorable prognostic factor31 in patients with metastatic colorectal cancer (mCRC) and are estimated around 8–12% of patients with mCRC32,33. This evidence concerns the gene BRAF and metastatic colorectal cancer.